Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Second Quarter 2018 Financial Results

SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 28, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock

SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 27, 2018 16:01 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Commencement of Public Offering of Common Stock

SAN DIEGO, June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 20, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial

– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
April 09, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018

SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
January 17, 2017 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase...
September 30, 2015 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma

LA JOLLA, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid...